Clinical and pharmacological group: & nbsp

Other neurotropic drugs

Included in the formulation
  • Glycine
    pills n / az. 
    BIOTICS MNPK, LLC     Russia
  • Glycine
    pills n / az. 
    VERTEKS, AO     Russia
  • Glycine forte
    pills n / az. 
  • Glycine Fort Pharmaplant®
    pills n / az. 
  • Glycine-Bio Pharmaplant®
    pills n / az. 
    OZONE, LLC     Russia
  • Glycine-Canon
    pills n / az. 
  • Glycine-MCPP
    pills n / az. 
  • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    N.06.B.X   Other psychostimulants and nootropic drugs

    Pharmacodynamics:It is the inhibitory mediator of the central nervous system. Strengthens energy processes, increases oxygen consumption of tissues, normalizes blood supply, promotes the utilization of glucose in the brain. Improves thinking, dynamics of nervous processes in the brain, memory, has anticonvulsant activity and anti-anxiety action. Reduces motor excitability, organizes behavior. Normalizes sleep, reduces the toxic effects of alcohol and other drugs that depress the central nervous system.

    Pharmacokinetics:After sublingual application, the maximum concentration in the blood plasma is reached after 5-10 minutes.

    Metabolism in the liver. Penetrates through the blood-brain barrier. Elimination by the kidneys.

    The half-life is 5 hours. Elimination by the kidneys.

    Indications:It is used for the treatment of organic and functional diseases of the central nervous system, with ischemic stroke. Used in the case of deviant forms of behavior of children and adolescents, stressful situations, lowering mental capacity, withdrawal from alcoholism.

    V.F40-F48.F48.0   Neurasthenia

    V.F40-F48.F45.3   Somatoform dysfunction of the autonomic nervous system

    V.F70-F79.F79   Mental retardation, unspecified

    V.F00-F09.F01   Vascular dementia

    V.F00-F09.F03   Dementia, unspecified

    V.F10-F19.F10.2   Mental and behavioral disorders caused by alcohol use - addiction syndrome

    V.F10-F19.F10.3   Mental and behavioral disorders caused by alcohol use - withdrawal symptoms

    V.F30-F39.F34.1   Dysthymia

    V.F40-F48.F41.2   Mixed anxiety and depressive disorder

    VI.G40-G47.G45   Transitory transient cerebral ischemic attacks [attacks] and related syndromes

    VI.G90-G99.G92   Toxic encephalopathy

    VI.G90-G99.G93.4   Encephalopathy, unspecified

    IX.I60-I69.I63   Cerebral infarction

    IX.I60-I69.I67.2   Cerebral atherosclerosis

    IX.I60-I69.I67.4   Hypertensive encephalopathy

    Contraindications:Individual intolerance.

    Carefully:Hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category B. It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.

    Dosing and Administration:

    Use in children

    Sublingually or sub-bougally, at the age of up to 3 years: 0.05 grams (1/2 tablet) 2-3 times a day for 1-2 weeks, then 1 time per day for 7-10 days. For children over 3 years of age, the same doses apply as in adults.

    Adults

    Sublingually or subbekalno, regardless of food intake, 100-200 mg 3 times a day.

    With ischemic stroke: 1 g sublingually or buccally with 1 teaspoon of water at a time, then 100-200 mg (1-2 tablets) 2-3 times a day for 30 days.

    The highest daily dose: 1 g.

    The highest single dose: 1 g.

    Side effects:Allergic reactions.

    Overdose:Cases of overdose are not described.

    Interaction:Strengthens the effectiveness of anticonvulsants, prolongs the action of barbiturates.

    Reduces the severity of the toxic effects of antidepressants, anticonvulsants, neuroleptics.

    Special instructions:As a 1.5% solution, not conducting electrical current, is used in urology in transurethral electrosurgical interventions.

    Instructions
    Up